Senotherapeutics for Knee Osteoarthritis
Medicinal Research Reviews · 28.07.2026
DOI: 10.1002/med.70082 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 28.07.2026. Verfasst von Ezgi Duman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Lehrstuhl für Regeneration Muskuloskelettaler Gewebe und Lehrstuhl für Orthopädie, Orthopädische Klinik König-Ludwig-Haus, Universität Würzburg, Würz…. Die Arbeit nennt 253 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, European Cooperation in Science and Technology, H2020 Marie Skłodowska-Curie Actions.
Abstract (Originalsprache)
Osteoarthritis (OA) is a chronic disease that imposes a significant economic burden and deteriorates quality of life. Nevertheless, current therapeutic options for OA are limited to symptomatic remedies. As such, there is a high interest in novel methods for treating or preventing OA. One of the most promising medication modalities is through the clearance of cells that are cell cycle arrested but resistant to apoptosis, termed senescent cells. Additionally, these cells are also resistant to alternative programmed cell death modes, such as ferroptosis and pyroptosis. Senescent cells tend to accumulate with age due to increasing cellular and genetic damage. These cells can release inflammatory factors and signaling molecules termed senescence‐associated secretory phenotype (SASP). In addition to triggering an inflammatory milieu in joints, SASP can also induce senescence in other cells through autocrine signaling. It has been shown via in vitro and in vivo tests that clearance of senescent cells through a class of drugs known as senolytics, or neutralization of SASP with senomorphics, can improve OA pathogenesis. Following these results, several clinical trials have been conducted to evaluate the efficacy of senotherapeutics against knee OA. Yet there remains a need for a comprehensive assessment of safety and optimization of senotherapeutic treatment regimens for knee OA. To this end, a better understanding of molecular mechanisms behind chondrocyte senescence and knee OA pathogenesis is necessary. Identification of novel compounds that can specifically target chondrocyte senescence pathways can assist in developing more effective therapies against OA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Lehrstuhl für Regeneration Muskuloskelettaler Gewebe und Lehrstuhl für Orthopädie, Orthopädische Klinik König-Ludwig-Haus, Universität Würzburg, Würzburg, Deutschland.
- Labor für Experimentelle Unfallchirurgie, Klinik und Poliklinik für Unfallchirurgie, Universitätsklinikum Regensburg, Regensburg, Deutschland.
ORCID-Profile: Girish Pattappa, Denitsa Docheva
Förderung
- Deutsche Forschungsgemeinschaft
- European Cooperation in Science and Technology
- H2020 Marie Skłodowska-Curie Actions
Zitieren
APA
Duman, E., Pattappa, G., Pann, P., Reppenhagen, S., Rudert, M., Angele, P., & Docheva, D. (2026). Senotherapeutics for Knee Osteoarthritis. Medicinal Research Reviews. https://doi.org/10.1002/med.70082
Vancouver
Duman E, Pattappa G, Pann P, Reppenhagen S, Rudert M, Angele P, et al. Senotherapeutics for Knee Osteoarthritis. Medicinal Research Reviews. 2026. doi:10.1002/med.70082
BibTeX
@article{Duman2026,
author = {Duman, Ezgi and Pattappa, Girish and Pann, Patrick and Reppenhagen, Stephan and Rudert, Maximilian and Angele, Peter and Docheva, Denitsa},
title = {Senotherapeutics for Knee Osteoarthritis},
journal = {Medicinal Research Reviews},
year = {2026},
doi = {10.1002/med.70082}
}
EUVIMED